INTRODUCTION
The MAPK (mitogen-activated protein kinase) p38 is a key signalling protein involved in regulating the production of multiple inflammatory mediators. Therefore p38 MAPK has been the target of intensive research in academic groups and in many different pharmaceutical companies [1] . p38 belongs to the MAPK family of serine/threonine kinases that share a common overall structure and a similar mode of activation via phosphorylation at the activation loop by upstream activators, including MKK3 (MAPK kinase 3) and MKK6 for p38 MAPK (for a review, see [2] ). Of the four p38 MAPK isoforms, p38α and p38β are ubiquitously expressed and in inflammatory cells p38α is the most prominent. Many different extracellular stimuli activate p38 MAPK, among them inflammatory cytokines, LPS (lipopolysaccharide) and other bacterial products, and different stressors such as thermal, mechanical or hypoxic insults [3] . In turn, p38 MAPK directly phosphorylates important transcription factors including MEF2 (myocyte enhancer factor 2) and ATF2 (activating transcription factor 2). p38 MAPK also controls the activation state of downstream kinases, such as MAPKAPK (MAPK-activated protein kinase) 2 and 3, that, in turn, phosphorylate HSP27 (heat-shock protein 27) and other cellular proteins. A p38-dependent route regulates the stability and expression of mRNAs coding for cytokines such as TNFα (tumour necrosis factor α), IL (interleukin)-1β, IL-6 and IL-8 [4] . In the context of pain, p38 MAPK is activated in the spinal cord in several models of chronic pain, and pain hypersensitivity can be transiently blocked by administration of p38 MAPK inhibitors [5] [6] [7] [8] . These findings indicate that p38 MAPK may be an interesting target for the development of therapeutic drugs to treat chronic inflammatory pain. However, so far human clinical trials using p38 MAPK inhibitors have not yielded the expected results [9] .
p38 MAPK is able to specifically interact with upstream regulators and also with downstream substrates by virtue of a specific site called docking domain that is situated opposite the activation loop [2] . The specific features of these interactions have been characterized in detail and the structure of p38α cocrystallized with peptides derived from the interacting motifs in MKK3b and MEF2A has been resolved [10] . Interestingly, the interactions mediated by this docking domain can be regulated by means of phosphorylation of either the substrate or p38 MAPK itself [11] . This characteristic provides a feasible mechanism for intervention into the p38 MAPK route by providing a target for therapeutic drugs that is potentially more specific for p38 MAPK than its currently most widely targeted domain, the ATP-binding site. The site shares a high overall homology with that of other protein kinases [12] , and this probably underlies the failure of the first and second generation ATP-site targeted compounds tested during human clinical trials [1] . Consequently, the need for novel strategies utilizing unexplored interactive domains in p38 MAPK is an avenue that certainly deserves further research. Previously, we have described that p38 MAPK can be phosphorylated at the docking groove resulting in reduced binding of upstream kinases and downstream targets and therefore impairing its activity [11] . On the basis of those findings, we performed a virtual screening of a chemical library of compounds to search for potential novel p38 MAPK inhibitors targeting the docking groove.
MATERIALS AND METHODS

VS (virtual screening)
All VS calculations were performed within the automated platform VSDMIP [13, 14] . For the sake of clarity, below we briefly describe the main steps comprising the protocol.
Receptor preparation
The 3D structure of p38 MAPK, taken from a complex with the MEF2A peptide (PDB code 1LEW) [10] , was used as the receptor. All atoms other than those from the receptor were removed. AMBER ff99 force field [15] was then used to assign atom types and charges for each atom in the receptor. The addition of missing hydrogen atoms and computation of the protonation state of ionizable groups at pH 6.5 were carried out using the H + + Web server [16] , which relies on AMBER parameters and finite difference solutions to the Poisson-Boltzmann equation. A salt concentration of 0.15 M and an internal and external dielectric constant of 4 and 80 respectively were used.
Binding site definition and characterization
To delimit the binding site we selected MEF2A as the core around which to build the docking box by adding a 5.0 Å cushion to the maximum dimensions of the peptide. A equally spaced grid of 0.5 Å was then built, and CGRID [17] was used to calculate the protein interaction fields (a 12-6 Lennard-Jones term and an electrostatic term modelled with a sigmoidal dielectric screening function) using common atom probes (C, N, O, S, P, H, F, Cl, Br and I) at each grid point. Next, benzene, water and methanol probes were docked using CDOCK [17] to generate intermolecular interaction energy maps aimed at capturing the most probable areas of interest for hydrophobic, hydrophilic and hydrogen bond interactions respectively. These areas were further compressed into Gaussian functions using the GAGA algorithm [18] producing a negative image of the interaction site. The putative active ligands in the library must conform to this approximate shape.
Chemical library preparation
Ligands for VS consisted of a selection of ∼10 6 non-redundant molecules obtained from the publicly available ZINC database [19] , mainly from ChemBridge and ASINEX, in SMILES format [20] . Multiple protonation states and tautomeric forms were considered as implemented by default in ZINC. The molecules were then processed within VSDMIP as: (i) conversion from SMILES to 3D MOL2 using CORINA (http://www.molecular-networks. com/products/corina); (ii) atomic charge calculations with MOPAC [22] (MNDO ESP method) on every single structure provided by CORINA; and (iii) atom type assignment according to the AMBER ff99 force field and conformational analysis using ALFA [23] .
Filter 1
An initial filter was performed with the docking program DOCK to quickly discard those molecules that do not geometrically fit within the binding site. The spheres needed by DOCK were those generated previously with GAGA. We used DOCK contact as the scoring function, normalizing the score values (score i ) by converting them into ZScores using mean (average score) and S.D. (σ ) values [ZScore i = (score i − average score)/σ ]. Only those molecules with a ZScore beyond a cut-off value of 2.5 were selected (out of 45488) and passed on to the next step.
Filter 2
Selected molecules from the previous step were docked with the more accurate docking algorithm CDOCK. CDOCK exhaustively docks each molecule within the binding site of the receptor using the interaction energy grids calculated previously with CGRID. This was achieved by an exhaustive exploration of the location and orientation of each molecule by positioning its centre of mass on grid points and performing discrete rotations of 27
• on each axis (poses). Finally, the energy of the poses was evaluated by the MM (molecular mechanics) force-field scoring function implemented in CDOCK, which, beside including a 12-6 Lennard-Jones term and an electrostatic term modelled with a sigmoidal dielectric screening function, also accounts for ligand and receptor desolvations as well as for hydrogen-bonding interactions [24] .
MD simulations and MM-GBSA calculations
The top-ranked 200 molecules according to CDOCK's scoring function were subjected to better binding free energy estimation by a combination of MD trajectories and MM-GBSA [25] calculation on these trajectories. The 200 complexes were hydrated by using boxes containing explicit water molecules with added counter ions to maintain electroneutrality, energy minimized, heated (20 ps) and equilibrated (100 ps). After equilibration, MD trajectories were continued for 200 ps. From this last part, structures were homogenously sampled each 10 ps and stored for post-processing. All the simulations were performed at constant pressure and temperature [1 atm (1 atm≡101.325 kPa) and 300 K] with an integration time step of 2 fs. SHAKE [26] was used to constrain all the bonds involving hydrogen atoms at their equilibrium distances. Periodic boundary conditions and the Particle Mesh Ewald methods were used to treat long-range electrostatic effects [27] . AMBER ff99 and TIP3P [28] force fields were used in all cases. Finally, the effective binding free energies were qualitatively estimated using the MM-GBSA approach, which calculates the free energy of binding as a sum of a MM interaction term, a solvation contribution thorough a GB (Generalized Born) model and a SA (surface area) contribution to account for the non-polar part of desolvation. A 12-6 LennardJones term was used to model the MM contribution. For the GB model, the solute dielectric constant was set to 4, whereas that of the solvent was set to 80, and the dielectric boundary was calculated using a solvent probe radius of 1.4 Å. The SA contribution was approximated as a linear relationship to the change in SASA (solvent accessible SA)
where a is 0.092 kcal/mol, b is 0.00542 kcal·mol − 1 ·Å − 2 , G np is the SA contribution, and the change in SASA refers to the complex SASA minus the sum of that of the protein and the ligand alone. In addition, interaction energy analysis between the ligands and the more relevant residues in the binding site were computed (with MM-GBSA). All the trajectories and analysis were performed using the AMBER 8 program and associated modules [29] .
Selection of candidates
Averaged structures along the trajectories were obtained and energy-minimized in a vacuum with the ff99 force field, without periodic boundary conditions and during 1000 steps (the first 500 with the steepest descent method and the rest with the conjugated gradient) solely to alleviate the possible clashes that may be originated by averaging the co-ordinates. These structures were used for graphical representation and comparison of the binding modes. From the highest-scoring compounds, and upon visual examination, 18 candidates were finally selected, purchased (see below) and tested experimentally. All visualizations were done within the molecular graphics program PyMOL (http://www.pymol.org). Unfortunately, not all the compounds were available from the vendors. In these cases similarity search was performed employing two complementary strategies based on: (i) the 2D topological representation of the molecules and the search/compare engine implemented in ZINC; and (ii) the 3D structure of the molecules, the shape-matching algorithm implemented in the program ROCS [31] , and the ZINC database as implemented in VSDMIP. The similarity between structures was assessed by the Tanimoto coefficient (T c ), selecting only those candidates with a T c 0.9 to be docked into the receptor and for further analysis. The final goal was to choose one or two purchasable analogues for each not-found compound presenting as similar interactions as possible when compared with the originally selected molecules.
H2L (hit-to-lead) optimization
The scheme for the H2L optimization cycle is shown in Figure 1 . A typical optimization step involves a finer docking study of the best compounds from the experimental assays over an energy-minimized MD-averaged structure followed by MD simulation and MM-GBSA analysis. In brief, for every docked molecule we: (i) selected the 100 best docking solutions; (ii) clustered them according to their structural resemblance; (iii) selected a representative structure from each of the cluster based on its CDOCK energy; (iv) ran a MD simulation for a period of up to 10 ns; (v) estimated their free energy of binding using the MM-GBSA method; (vi) selected the best pose based on the MM-GBSA energy; and (vii) visually inspected and analysed the structures from (vi). In this last analysis, the essential ligandreceptor interactions were evaluated to define possible chemical modifications to enhance binding towards the receptor. These suggestions represented new candidates for synthesis. Following synthesis, the compounds are experimentally assayed and the theoretical models revised. This process (i)-(vi) was performed twice resulting in two final lead compounds.
Chemical synthesis
N-(5-chloro-2-methylphenyl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-
amine (FGA-19) was synthesized as follows: a solution of Nbd-Cl (4-chloro-7-nitrobenzofurazan; 798.2 mg; 4 mM) and 5-chloro-2-methylaniline (1.26 g; 8 mM) in N,N-dimethylformamide (50 mM) was refluxed for 24 h. The reaction mixture was then allowed to warm up to room temperature (25 • C), quenched with a saturated aqueous sodium bicarbonate solution, extracted with ethyl ether (3×30 ml), and the combined organic layers were washed with a saturated aqueous sodium chloride solution, dried (sodium sulfate), filtered and concentrated to give a crude oil which was purified using chromatography over silica gel and hexanes/ethyl acetate (7:3) as eluent. The desired compound was obtained as a red oil (608 mg; yield = 50 %), which was crystallized [MeOH/H 2 O (1:1)] to afford pure compound FGA-19 as red crystals.
Compounds FGA-17, FGA-20, FGA-23, FGA-29, FGA-32 and FGA-34 were synthesized as follows: a solution of NbdCl (798.2 mg; 4 mM) and the corresponding aniline (8 mM) in ethyl acetate (50 ml) was refluxed for 48 h. The reaction mixture was then allowed to warm up to room temperature and worked up and purified as described above. The yields and physical state of each one of these final products are specified in Table 1 .
Animals
Female C57BL/6 mice (12-14 weeks old) and female mice with a cell-specific reduction of GRK2 (G-protein-coupled-receptor kinase 2) in LysM (lysozyme M)-positive macrophages (LysM-GRK2 + / − mice) were used [32] . LysM-Cre mice and GRK2-fLox mice were obtained from Jackson Laboratories to generate LysM-GRK2 + / − and control LysM-GRK2 + / + mice [WT (wild-type) littermates]. Peritoneal macrophages were collected from global GRK2 hemizygous male mice [33] as described in [11] . All mice were bred and maintained in the animal facility of the University of Utrecht, The Netherlands or of the Universidad Autonoma de Madrid, Spain. Experiments were performed in accordance with international guidelines and approved by the experimental animal committee of each institution.
Mice received an intraplantar injection in the hind paw of 20 μl of λ-carrageenan [2 % (w/v); high dose; SigmaAldrich] or 5 μl of λ-carrageenan [1 % (w/v); low dose; Sigma-Aldrich] diluted in saline. Heat withdrawal latency times were determined using the Hargreaves test (IITC Life Science) as described in [34] . Paw thickness was measured using a Digimatic micrometer (Mitutoyo). Different concentrations of FGA-19 were applied intrathecally (5 μl/mouse) while the animals were under light isoflurane anesthaesia. All behavioural experiments were performed by an experimenter blinded to the treatment and mice were assigned to the treatment groups in a randomized fashion.
Fluoro-Jade B staining
At 2 days after intrathecal FGA-19-or vehicle-treated mice were deeply anaesthetized with sodium pentobarbital (50 mg/kg of body mass; intraperitoneal) and perfused intracardially with 4 % paraformaldehyde in PBS. Spinal cords were removed and paraffin-embedded. Spinal cord sections were deparaffinized, pretreated with 0.06 % potassium permanganate and stained with 0.001 % Fluoro-Jade B solution (Millipore Bioscience Research Reagents) in 0.1 % acetic acid to visualize the damaged neurons.
TNFα determination in tissue lysates
Spinal cords were homogenized in PBS and centrifuged at 13 000 g for 15 min at 4
• C. The TNFα content in the supernatant was quantified by ELISA (R&D systems).
Electrophoresis and Western blotting
Proteins were resolved by SDS/PAGE (7.5 % gel), and transferred on to nitrocellulose membranes for Western blotting analysis. The antibodies used were: anti-p-p38 ( 
In vitro inhibition of p38 MAPK activation and activity by FGA-19
Purified p38α (75 nM) was pre-incubated for 15 min at 30
• C with FGA-19 at concentrations between 0.5 and 50 μM in buffer [25 mM Tris/HCl (pH 7.5), 50 μM EGTA, 50 μM NaVO 4 and 0.05 % 2-mercaptoethanol]. Constitutively active MKK6 (10 nM; Millipore), magnesium acetate (2.5 mM) and ATP (25 μM) were added and a kinase reaction was performed for 15 min at 30
• C. The reaction was terminated by adding Laemmli buffer and proteins were resolved by SDS/PAGE (7.5 % gel) to detect p-p38 (pTGY) by Western blot analysis. In vitro activity assays were performed using recombinant activated p38α (1 nM; ProQinase), which was pre-incubated for 15 min at 30
• C with the small molecule in the same buffer. Full-length GST (glutathione transferase)-MEF2A (10 nM; purified in our laboratory), magnesium acetate and ATP were added and the kinase reaction was allowed to proceed. p-MEF2A was detected by Western blot analysis.
Pull-down assay
To examine the interaction between p38 MAPK and its substrate MAPKAPK2 in the presence or absence of FGA-19, fulllength mouse p38α-GST and full-length MAPKAPK2-His were produced in bacteria and purified using the Profinia TM Purification Protein system (Bio-Rad Laboratories) according to the manufacturer's protocols. p38-GST (150 nM) was preincubated with 25 μM FGA-19 or vehicle (0.05 % DMSO) in binding buffer [25 mM Tris/HCl (pH 7.5), 0.25 M NaCl, 10 mM MgCl 2 and 5 mM NaF] at 30
• C for 30 min. Then 150 nM MAPKAPK2-His was added for 15 min and the reaction was incubated with glutathione-Sepharose 4B (GE Healthcare) at 30
• C for 15 min. Beads were washed twice with washing buffer [25 mM Tris/HCl (pH 7.5), 0.25 M NaCl, 10 mM MgCl 2 , 5 mM NaF and 0.5 % Triton X-100]. GST-p38-bound proteins were analysed by SDS/PAGE (7.5 % gel) and Western blot analysis. THP-1 cells, growing in the exponential phase, were resuspended in RPMI 1640 medium to a final concentration of 2×10 6 cells/ml and distributed in 24-well plates. FGA molecules were added to the wells to a final concentration ranging from 10 nM to 100 μM and plates were incubated at 37
• C and 5% CO 2 in a humidified atmosphere. Cells were stimulated 1 h later with LPS to a final concentration of 0.5-2 μg/ml and incubated for 3 h followed by centrifugation (2000 g for 10 min at 4
• C) to pellet the cells. Supernatants were collected and stored at − 20
• C for further analysis. TNFα secretion was measured by ELISA (GE Healthcare) following the manufacturer's instructions.
Cell culture and viability analysis
THP-1 human monocytic cells were maintained in suspension in RPMI medium containing 10 % FBS, 1 mM pyruvate, 2 mM glutamine and antibiotics. The potential in vitro toxicity of FGA-19 was quantified using PI (propidium iodide), which specifically labels dying cells. Cells were resuspended in buffer (PBS, 1 % BSA, 1 % FBS, 0.01 % NaN 3 and 1 μg/ml PI), kept on ice for 30-60 min and then analysed by flow cytometry using a FACSCalibur cytometer (Becton Dickinson). The data were analysed with Cell Quest Pro Software (Becton Dickinson).
Statistical analysis
All results are means + − S.E.M. Measurements were compared using Student's t test or one-way ANOVA followed by Tukey's post-hoc test, or two-way ANOVA with Bonferroni's post-hoc tests using Prism 5 software.
RESULTS
VS and identification of a lead compound
The VS protocol used in the present study is summarized in Figures 1(A) and 1(B) and is briefly described in the Materials and methods section. An essential part of the procedure comprises characterization of the shape of the active site (the docking groove of p38 MAPK). For this purpose we used the space occupied by the MEF2A peptide co-crystalized with p38 MAPK and the GAGA algorithm to obtain a negative image of the binding site. Although different X-ray structures were available to be used as the receptor for the VS, we selected the one contained in the PDB code 1LEW because of its high resolution, in particular in the area where the docking was to be performed. Moreover, superimposition of several structures (PDB codes 1LEW, 3P4K, 1P38, 2FSL, 2FSM, 2FSO and 2FST) showed very low RMSD values considering equivalent C α carbon atoms, supporting the use of a single rigid receptor structure in the docking process.
Upon characterizing the binding site, a library of around ×10 6 compounds was first screened using DOCK and the negative image of the binding site. After applying a Z-Score cut-off value of 2.5 on the DOCK ranked list, 45488 molecules passed on to the next step. These molecules were then re-docked with CDOCK and scored with its MM energy function, which explicitly included solvent and hydrogen-bonding terms. The 200 highest-scoring compounds were submitted to MD simulation in explicit solvent and their binding energies estimated and pair-wise decomposed by MM-GBSA calculation over a large collection of snapshots homogeneously sampled along the trajectories. Finally, from the top scoring compounds, and upon visual examination, 18 candidates were selected, purchased and tested experimentally. The most promising candidate, the highly symmetrical compound 978604, was not commercially available. In addition, and according to Lipinski's RoF (rule of five) [35] , this compound presented a very high logP value [36] (∼8.00). Therefore a similarity search was performed resulting in a new compound, 5380, that was found to be structurally equivalent to one half of the original one due to its symmetry. On the one hand, 5380, due to its smaller size, is better suited for chemical modifications, but, on the other hand, its logP value was drastically reduced to within the RoF (5.00) criteria. This compound was purchased, experimentally tested and submitted to two optimization rounds. From the first optimization round a lead candidate was obtained, FGA-19, with enhanced pharmacological profile and logP value (4.35). Upon studying the binding mode of FGA-19, a second optimization cycle led to the discovery of a second lead compound, FGA-29, in which the methyl group of FGA-19 was replaced by a hydroxy moiety, thus further reducing its logP value (3.68).
Owing Figure 1D ). In particular, the interactions with Asn 159 and Glu 160 , which are geometrically optimized in FGA-29 compared with FGA-19, are mainly hydrophobic in nature and account for a total energy difference of approximately 2 kcal/mol. However, this magnitude is within the margin of error for these calculations and, therefore, no firm conclusions can be drawn regarding possible differences in their potential activities, which is in agreement with the experimental observations.
In vitro effects of FGA-19 on p38 MAPK activation and inhibition of the p38 MAPK route in human monocytic cells
We next set out to investigate the possible effects of the FGA-19 compound on p38 MAPK in an in vitro kinase activity assay using purified p38 MAPK-dependent phosphorylation of a well-characterized docking-dependent p38 MAPK substrate, the MEF2A protein. When adding increasing doses of the FGA-19 molecule to the reaction mix containing the active kinase and a saturating amount of substrate in the presence of ATP, we observed a dose-dependent inhibition of p38 MAPK-mediated phosphorylation of MEF2A at the specific site targeted by this kinase (Thr 312 ) (Figures 2A and 2B ). Densitometric analysis of the Western blotting data of MEF2A phosphorylation in the presence of increasing amounts of FGA-19 in several experiments revealed an estimated mean inhibitory concentration (IC 50 ) of 6.31 + − 2.32 μM. An almost complete inhibition of p38 MAPK activity towards MEF2A was observed at the 50 μM dose (Figures 2A and 2B) .
Next we analysed the effects of the FGA-19 compound on the p38 MAPK signalling route in the human monocytic cell line THP-1. As shown in Figures 2(C) and 2(D) , in the presence of FGA-19 we detected clear inhibition of p38 MAPK phosphorylation at the activation loop by upstream kinases. FGA-19 also inhibited the activity of p38 MAPK in THP-1 cells as measured by a decrease in the phosphorylation of the downstream substrates MAPKAPK2 and HSP27. Quantification of these inhibitory effects of FGA-19 revealed a ∼80 % inhibition for phosphorylation of p38 MAPK and ∼100 % inhibition for MAPKAPK2 phosphorylation at the 5 μM dose of FGA-19 ( Figures 2C and 2D) . Interestingly, no feedback activation effects were detected at the 1 μM dose for the JNK or ERK1/2 pathways ( Figure 2D, lower panel) and, in fact, both kinases appear to be inhibited to a certain extent by FGA-19 at the highest dose tested (5 μM), although with a much lower efficacy compared with the effect observed on the p38 MAPK pathway Interestingly, as shown in Figure 2 (E), FGA-19 was capable of impairing the in vitro interaction between p38 MAPK and the docking-dependent substrate MAPKAPK2, which was almost absent from p38 MAPK sediments in the presence of FGA-19, whereas it was clearly detected in the vehicle (DMSO) control samples. These results suggest that competitive inhibition towards docking-dependent partners is a probable mechanism for the actions of FGA-19 in agreement with the kinetic constants of the phosphorylation of MEF2 by constitutively active p38 MAPK in the presence or absence of FGA-19 (Supplementary Table S1 at http://www.biochemj.org/bj/459/bj4590427add.htm)
A broad specificity analysis was performed using a commercially available kinase screen (MRC-PPU Express Screen; International Centre for Kinase Profiling, University of Dundee, Dundee, U.K.). As shown in Supplementary Table S2 (http://www. biochemj.org/bj/459/bj4590427add.htm), FGA-19, at a dose of 10 μM, has little or no effect on a variety of kinases representative of the different groups comprising the human kinome. In agreement with its docking-groove-targeting design, FGA-19 had no inhibitory activity on p38α in this screening, since this assay is performed using MBP (myelin basic protein) as a substrate, a protein that apparently lacks a functional docking site [37] .
The effects of FGA-19 were then analysed in the wellestablished cellular system of cytokine secretion by THP-1 cells stimulated with LPS [4] . Secretion of TNFα by these cells is p38 MAPK-dependent, and thus this system has been broadly utilized to study the effects of different p38 MAPK inhibitors. As shown in Figure 2 (C), FGA-19 has a dosedependent inhibitory effect on TNFα secretion in this cell system with an IC 50 of 1.8 + − 0.006 μM reaching an almost maximal inhibition at the 10 μM concentration. For comparison, the IC 50 value for SB203580 (a commercially available p38 MAPK inhibitor targeting the ATP-binding site) in the same system was 1 μM (results not shown), and the effect of SB203580 at the 10 μM dose was similar to that obtained for FGA-19. Of note, we did not detect significant cell death, as determined by FACS analysis of PI-stained cells, at concentrations up to 100 μM FGA-19, indicating that there was no cellular toxicity ( Figure 3A) .
Identification of the structural determinants of the inhibitory effect
Comparative analysis of FGA-19 and several structurally related compounds, all belonging to the benzo-oxadiazol family, allowed us to conclude that the substituents in positions 2 and 5 of the phenyl ring are essential for the inhibitory activity towards p38 MAPK. When the substituents in positions 2 and 5 present in the FGA-19 molecule (a chloride and a methyl group respectively) are located in other positions of the phenyl ring (as in the FGA-17, FGA-20 and FGA-23 compounds), the IC 50 value for inhibition of monocyte TNFα secretion decreased by at least one logarithmic unit ( Figures 3B and 3C , and Table 2 ). This was the case for Cl and CH 3 Table 2 ). Taken together, these results establish that a substituent at positions 2 and 5 in the phenyl ring is essential for the described inhibitory activity and, furthermore, that a chloride at position 5 and a methyl group at position 2 are the most effective chemical groups among those tested so far.
In vivo effect of FGA-19 on inflammatory hyperalgesia
To determine the in vivo efficacy of FGA-19, we examined its effect in the high-dose carrageenan model of persistent inflammatory hyperalgesia in C57BL/6 mice. In response to intraplantar injection of 20 μl of 2 % carrageenan, mice developed thermal hyperalgesia that lasted at least 11 days ( Figure 4A ). We injected increasing doses of FGA-19 intrathecally at day 6 after intraplantar carrageenan. The data show that hyperalgesia completely resolved in response to a single injection of 1 μg of FGA-19. A lower dose of 0.5 μg of FGA-19 transiently inhibited carrageenan-induced hyperalgesia ( Figure 4A ). For comparison, we used the established p38 MAPK inhibitor SB239063. At the maximal dose that could be injected using 20 % DMSO as a solvent, i.e. 5 μg of SB239063, carrageenan-induced hyperalgesia was only transiently attenuated ( Figure 4A ). Thermal sensitivity was not affected by FGA-19 in the control saline-treated mice ( Figure 4B ). The structurally similar FGA-23 compound, that in vitro has an IC 50 value of >100 μM, did not have any effect on the course of carrageenan-induced hyperalgesia ( Figure 4B ). To determine whether the inhibition of hyperalgesia by FGA-19 was associated with cellular damage in the spinal cord, we analysed the effect of FGA-19 on staining with FluoroJade B, a widely used marker of neurodegeneration. We did not observe an increase in Fluoro-Jade B-positive cells in the spinal cord at 48 h after injection of 1 μg of FGA-19, indicating that there was no effect of this dose of FGA-19 on neuronal cell death ( Figure 4C ). Our cell culture experiments showed that FGA-19 inhibits LPS-induced TNFα production ( Figure 2C) , and spinal cord production of pro-inflammatory cytokines such as TNFα is known to contribute to the persistent hyperalgesia in the carrageenan model of inflammatory pain [38, 39] . To investigate whether in vivo FGA-19 treatment affects TNFα levels, we injected carrageenan or saline intraplantarly, followed by intrathecal injection of FGA-19 or vehicle on day 6, and then isolated the lumbar spinal cord 2 days later for analysis of TNFα levels by ELISA. As anticipated, intraplantar injection of carrageenan caused a significant increase in spinal cord TNFα ( Figure 4D ). Intrathecal FGA-19 treatment significantly inhibited this carrageenan-induced rise in spinal cord TNFα levels. FGA-19 alone did not have any effect on TNFα production in the spinal cord ( Figure 4D ). At 6 days after intrathecal FGA-19 treatment the mice still showed increased paw thickness and redness, indicating that intrathecal FGA-19 treatment did not directly affect peripheral inflammatory activity ( Figure 4E ).
Since p38 MAPK can be phosphorylated by GRK2 at the docking groove [11] , it was tempting to hypothesize that cells with decreased levels of GRK2 and lower amounts of dockingsite-phosphorylated p38 MAPK protein would display differential susceptibility to inhibition via docking-targeted compounds. For instance, inflammatory cells from patients with autoimmune diseases or murine models of these diseases contain decreased levels of GRK2 [40] , and this is recapitulated in hemizygous GRK2 macrophages [11] . We thus set out to investigate whether TNFα secretion by macrophages isolated from GRK2 + / − mice was differentially inhibited by FGA-19 when compared with macrophages from WT mice. Interestingly macrophages collected from GRK2
+ / − mice were found to be more sensitive to FGA-19-dependent blockade of TNFα secretion than WT macrophages ( Figure 5A ). Table 2 Comparative analysis of the effects on TNFα secretion of FGA-19 and several structurally related compounds belonging to the benzo-oxadiazol family THP-1 cells were pre-incubated with the indicated doses of several benzo-oxidiazol-derived compounds for 1 h and stimulated with LPS for 3 h. TNFα secretion in cell supernatants was quantified using a TNFα ELISA kit and referred to the control (DMSO). Values were used to graphically approximate an IC 50 value in micromolar units. When the substituents in positions 2 and 5 present in the FGA-19 molecule (namely a chloride and a methyl group) are located in other positions of the phenyl ring, the IC 50 value for the inhibition of TNFα secretion by monocytic cells decreases. The next question we addressed is whether FGA-19 treatment also reverts the persistent hyperalgesia that develops in mice with a targeted deletion of GRK2 in LysM-positive macrophages/ monocytes. We have described previously that LysM-GRK2 + / − mice develop persistent hyperalgesia lasting at least 20 days in response to an intraplantar injection of a low dose of carrageenan (5 μl of a 1% solution) [11] . In this model of transient hyperalgesia, the pain response in WT mice resolves within 2 days [38] . The LysM-GRK2 + / − mice can be considered as a model of persistent post-inflammatory hyperalgesia as we do not observe ongoing peripheral inflammation (no redness or thick paws and no detectable increase in inflammatory cytokines in comparison with control paws [32] ). As shown in Figure 5(B) , intrathecal administration of FGA-19 also completely attenuated hyperalgesia in this model of post-inflammatory hyperalgesia. The lowest effective dose providing a long-lasting analgesic effect was 0.5 μg of FGA-19, which is lower than the 1 μg dose found in the high-dose carrageenan model in WT mice ( Figure 4A ).
DISCUSSION
The search for clinically applicable inhibitors of p38 MAPK has rendered, so far, no fruitful therapeutic results. The reasons underlying this lack of success include low efficacy in some cases and the identification of certain toxicities during clinical trials that were not uncovered in surrogate animal models of the different diseases tested [41] . These toxicities can have several aetiologies. On the one hand, first and second generation p38 MAPK inhibitors were designed to target the ATP-binding pocket of p38 MAPK, thus exploiting a common domain found in many different kinases, probably triggering off-target effects [1] . On the other hand, even when new allosteric site inhibitors were developed to overcome these problems, it became apparent that a strong down-regulation of the p38 MAPK pathway can trigger the up-regulation of other signalling pathways by virtue of the concomitant stimulation of interconnecting feedback mechanisms (see below). These final undesired consequences were apparently underestimated [3] . Lastly, the systemic administration of p38 MAPK inhibitors has been proven to induce toxicities in organs other than those important for the disease they were meant to combat, including the liver and brain [41] . For all these reasons, in the present study we set out to characterize a novel family of inhibitors that take advantage of the existence of docking domains in the p38 MAPK protein providing the possibility of modulating the activity and activation of this kinase independently of its intrinsic catalytic activity in a more subtle, but possibly more efficacious, manner. Our strategy relied on our previous results showing that p38 MAPK can be phosphorylated at the docking domain, specifically at Thr 123 of murine p38α. This phosphorylation of Thr 123 causes the loss of interaction with different p38-binding partners and reduced activation and activity of p38 MAPK [11] . On this basis, we performed a VS of a chemical library of compounds over a model based on pre-existing structures of p38 MAPK bound to peptides derived from upstream regulators or downstream substrates [10] . This search yielded the identification of compounds of different chemical nature that were analysed for their in vitro inhibitory capacity towards p38 MAPK activity or towards cytokine secretion induced by LPS in a human monocytic cell line. Only some molecules were inhibiting these events with IC 50 values in the micromolar range. Of these, the family of benzo-oxadiazol-based compounds described in the present study, with FGA-19 as a lead candidate, was found to have a biological effect both in cells and in two animal models of hyperalgesia. The fact that FGA-19 contains several putative sites susceptible for chemical modifications highlights this molecule as a good lead compound for further drug development strategies.
In vitro experiments support the notion that the biochemical mechanism of action of FGA-19 involves its ability to interfere with binding of docking-dependent substrates to p38 MAPK, as indicated by kinetic competition experiments and the inhibition of the pull down of purified MAPKAPK2 by p38 MAPK. Accordingly, FGA-19 does not efficiently inhibit the activity of p38 towards MBP, a substrate that does not rely on a functional docking site for its phosphorylation by members of the p38 MAPK family [37] . Moreover, 10 μM FGA-19 had little or no effect on the activity of a variety of kinases representative of the human kinome, supporting the notion that by targeting the docking groove of p38, FGA-19 displays less cross-inhibition with other kinases and thus increased specificity. However, the possibility exists that FGA-19 might interfere with the phosphorylation of specific docking-dependent substrates of other members of the p38 MAPK family, or of the related MAPK family members JNK1 or ERK1/2, and this will be the subject of future research. The strategy utilized to identify FGA-19 aimed at interfering with docking interactions between p38 MAPK and substrates or activators of p38 MAPK [11] . This particular characteristic was utilized as it could in principle yield a different mode of action leading to a less abrupt blockade of the pathway flow and thus, at least theoretically, less toxic effects. For instance, one of the off-target effects described for classical p38 MAPK inhibitors is the hyperactivation of the JNK cascade. This is thought to happen because strong inhibition of p38 MAPK can abrogate some negative-feedback loops that p38 MAPK maintains towards upstream kinases such as MLK2/3 (mixed lineage kinase 2/3) or TAK1 (transforming growth factor-β-activated kinase 1), which also function upstream of JNK [42] . Thus abolition of the negative feedback control exerted by the p38 MAPK branch redirects the pathway flow towards a higher activation of the JNK pathway. However, we did not detect increased activation of JNK in cells in the presence of FGA-19. If anything, the JNK pathway was inhibited, but to a lesser extent than the p38 MAPK route by FGA-19. These findings suggest that this type of unwanted effect may not occur for docking-based inhibitors or for inhibitors that do not fully ablate p38 MAPK catalytic activity. The possibility that the more refined and less potent inhibition of p38 MAPK, such as that obtained by FGA-19, can prevent other undesired side effects such as activation of cell death routes certainly deserves further investigation.
The in vivo effects of FGA-19 surpass those detected for other well-established p38 MAPK inhibitors in our mouse models of inflammatory pain, both in potency and in persistence of the pharmacological effect. Of note, the FGA-19 molecule is almost 10-fold as potent as the SB239063 inhibitor, since a 0.5 μg dose of FGA-19 exerts the same transient analgesic effect as 5 μg of SB239063 despite both molecules having similar molecular masses (368.40 g/mol for SB239063 and 304.45 g/mol for 
test). (B) LysM-GRK2
+ / − mice received a low dose of carrageenan (5 μl of 1% λ-carrageenan) and at day 6 mice were still hyperalgesic. At this time point, the mice received an intrathecal (i.t.) injection with different doses of FGA-19 and the percentage change in heat withdrawal latency was determined (n = 4). Results are means + − S.E.M.
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. Moreover, longer-lasting effects are detected in mice treated intrathecally with FGA-19 at the 1 μg dose, which abrogates inflammatory hyperalgesia for at least 5 days post-injection. For comparison, the pharmacological effect of SB239063 at the highest injectable dose did not last longer than 6 h. These results suggest that a very promising family of molecules could be derived from the benzo-oxadiazol structure to treat chronic inflammatory pain. Interestingly, recent studies have shown that mice with a reduced level of GRK2 in macrophages develop chronic hyperalgesia in response to inflammatory mediators that induce only transient hyperalgesia in WT mice (for a review, see [43] ). We therefore used these mice to test whether FGA-19 also inhibits the hyperalgesia in this model of post-inflammatory pain. We show that the persistent hyperalgesia that develops in LysM-GRK2 + / − mice is completely reversed by a single intrathecal injection of FGA-19. Moreover, macrophages obtained from GRK2 + / − mice are more sensitive to FGA-19-dependent blockade of TNFα secretion. These findings are particularly interesting because decreased levels of GRK2 are found in cells from patients with various inflammatory and autoimmune diseases [34] , and it is tempting to suggest that our docking-groove-targeting inhibitors would be especially suited for treatment of inflammation and pain in these conditions. Collectively, our findings indicate that FGA-19 is a potential candidate for the treatment of inflammatory hyperalgesia.
Clinical trials performed for p38 MAPK in the context of chronic inflammation have been unsuccessful so far due to both lack of efficacy and toxic effects [41] . However, although the importance of p38 MAPK in regulating nociception is wellestablished in mice and in humans [43] , few studies have been conducted so far to assess the efficacy of p38 MAPK inhibition in pain therapeutics. In particular, different laboratories have shown in rodent models that phosphorylated p38 MAPK is increased in spinal cord microglia after nerve ligation or spinal cord injury, which are two widely used models of chronic neuropathic pain. More importantly, intrathecal infusion of p38 MAPK inhibitors attenuates neuropathic pain in animal models (see references in [44] ). A small study has described a potent analgesic effect of p38 MAPK inhibition for post-surgical dental pain in humans [45] and several recent studies have described the contribution of p38 MAPK in animal models of neuropathic post-surgical and cancer pain [46] . It is also well-established that increased levels of phosphorylated p38 MAPK are detected in spinal cord microglia in animal models of chronic inflammatory pain (see references in [43] ). In agreement with these published studies, the results of the present study indicate that inhibition of spinal cord p38 MAPK by intrathecal administration of specific inhibitors efficiently reverses ongoing hyperalgesia ( [47] and the present study). However, the effect observed using these classic p38 MAPK inhibitors was much more transient than that observed using the FGA-19 inhibitor, which at a 1 μg dose shows an effect that lasted the 5-day duration of our experimental setup.
In conclusion, we present evidence that a novel family of small molecules targeting the docking groove of p38 MAPK, the benzo-oxadiazol-based compounds, are potent inhibitors of cytokine production in human monocytic cells. In addition, we show that a member of this family, the FGA-19 molecule, inhibits inflammatory and post-inflammatory pain in murine models. We suggest that this novel compound can represent the basis for further research on similar compounds for their specificity and potency in these models and, ultimately, for translation into a clinical setting.
